Compounds > mj347-81f4 a
Page last updated: 2024-11-12

mj347-81f4 a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

MJ347-81F4 A: isolated from Amycolatopsis structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16142519
CHEMBL ID263049
MeSH IDM0296051

Synonyms (4)

Synonym
mj347-81f4 a
CHEMBL263049
n-(1-carbamoylvinyl)-2-[(e)-[(2s,4s,5r,6s)-5-(dimethylamino)-4-hydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-dihydroxy-[(1r)-1-hydroxyethyl]-(1-methoxyethylidene)-hexaoxo-[?]yl]thiazole-4-carboxamide
DTXSID301028319
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID722059Antibacterial activity against Streptococcus pneumoniae CL2883 by turbidity method2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs.
AID375356Antibacterial activity against Enterococcus faecalis C21560 in liquid culture by turbidity method2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
AID375355Antibacterial activity against Streptococcus pneumoniae CL2883 in liquid culture by turbidity method2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
AID1867115Antibacterial activity against Clostridioides difficile SM8-6865 in CDAD golden hamster model assessed as log reduction in cecum bacterial content at 1.56 mg/kg, po administered twice daily for 4 days
AID208902In vitro antibacterial activity against Streptococcus aureus; 0.0070-0.032004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives.
AID1867110Antibacterial activity against Clostridioides difficile assessed as inhibition of bacterial growth by CLSI based agar dilution susceptibility analysis
AID208159Minimum concentration required to inhibit visible growth of penicillin-resistant Streptococcus pneumoniae A282722004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives.
AID1867112Antibacterial activity against Clostridioides difficile SM8-6865 in CDAD golden hamster model assessed as protection from lethal infection at 6.25 mg/kg, po administered twice daily for 4 days
AID1867109Selectivity ratio of MIC for Bacteroides fragilis ATCC 25285 to MIC for Clostridioides difficile
AID267866Antibacterial activity against methicillin-sensitive Enterococcus faecalis A206882006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of nocathiacin I analogues.
AID245057In vitro minimum inhibitory concentration against methicillin sensitive Streptococcus aureus A150902005Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8
Synthesis, in vitro, and in vivo antibacterial activity of nocathiacin I thiol-Michael adducts.
AID68409Minimum concentration required to inhibit visible growth of methicillin-resistant Enterococcus faecium A206882004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives.
AID722058Antibacterial activity against Enterococcus faecalis C21560 by turbidity method2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs.
AID1867113Antibacterial activity against Clostridioides difficile SM8-6865 in CDAD golden hamster model assessed as log reduction in cecum bacterial content at 6.25 mg/kg, po administered twice daily for 4 days
AID117650In vivo efficacy (sc) tested for protection against staphylococcus infections in mice; 0.3-2.82004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives.
AID249172In vivo protective dose required for mouse against systemic lethal Streptococcus aureus infection2005Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8
Synthesis, in vitro, and in vivo antibacterial activity of nocathiacin I thiol-Michael adducts.
AID377810Antibacterial activity against Staphylococcus aureus A150902005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical conversion of nocathiacin I to nocathiacin II and a lactone analogue of glycothiohexide alpha.
AID722060Antibacterial activity against Staphylococcus aureus MB2865 by turbidity method2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs.
AID117526Dose (iv) required against Staphylococcus aureus infected mice2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives.
AID1867114Antibacterial activity against Clostridioides difficile SM8-6865 in CDAD golden hamster model assessed as protection from lethal infection at 1.56 mg/kg, po administered twice daily for 4 days
AID67240In vitro antibacterial activity against Enterococcus faecalis2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives.
AID1867120Drug concentration in golden hamster caecum at 6.25 mg/kg, po measured after 24 hrs by LC-MS/MS analysis
AID1867111Antibacterial activity against Bacteroides fragilis ATCC 25285 assessed as inhibition of bacterial growth by CLSI based agar dilution susceptibility analysis
AID245077In vitro minimum inhibitory concentration against methicillin sensitive Enterococcus faecalis A206882005Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8
Synthesis, in vitro, and in vivo antibacterial activity of nocathiacin I thiol-Michael adducts.
AID267865Antibacterial activity against penicillin resistant Streptococcus pneumoniae A282722006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of nocathiacin I analogues.
AID21101Equilibrium water solubility was determined with amorphous powders at pH 42004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives.
AID722061Aqueous solubility of the compound in water containing 5% dextrose at pH 42013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs.
AID267867Activity against Staphylococcus aureus A15090 infected ICR mouse after 8 days2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of nocathiacin I analogues.
AID375353Antibacterial activity against Enterococcus faecalis2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
AID267864Antibacterial activity against methicillin-sensitive Staphylococcus aureus A150902006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of nocathiacin I analogues.
AID1867121Antibacterial activity against Clostridioides difficile assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by broth microdilution method
AID245096In vitro minimum inhibitory concentration against penicillin resistant Streptococcus pneumoniae A282722005Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8
Synthesis, in vitro, and in vivo antibacterial activity of nocathiacin I thiol-Michael adducts.
AID210217In vitro antibacterial activity against Streptococcus pneumoniae2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives.
AID267868Solubility at pH 4.02006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of nocathiacin I analogues.
AID1867119Drug concentration in golden hamster caecum at 6.25 mg/kg, po measured after 1 hr by LC-MS/MS analysis
AID375349Antibacterial activity against Staphylococcus aureus MB2865 in liquid culture by turbidity method2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
AID375361Inhibition of AT2 receptor2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
AID207653Minimum concentration required to inhibit visible growth of methicillin-sensitive Staphylococcus aureus A150902004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives.
AID377813Protective activity against Staphylococcus aureus A15090 infected in sc dosed mouse2005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical conversion of nocathiacin I to nocathiacin II and a lactone analogue of glycothiohexide alpha.
AID377811Antibacterial activity against Streptococcus pneumoniae A282722005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical conversion of nocathiacin I to nocathiacin II and a lactone analogue of glycothiohexide alpha.
AID377812Antibacterial activity against Enterococcus faecalis A206882005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical conversion of nocathiacin I to nocathiacin II and a lactone analogue of glycothiohexide alpha.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's6 (66.67)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.7430glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
linezolid
[no description available]		2.0510acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
nocathiacin i
nocathiacin I: structure in first source		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Staphylococcal
[description not available]		02.0210
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.0210
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0210